Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 诺诚健华(上交所代码:688428;港交所代码:09969)是一家商业化阶段的生物医药高科技公司,于2015年由拥有丰富新药研发及企业管理经验的崔霁松博士和世界著名结构生物学家施一公院士联合创立。我们为恶性肿瘤和自身免疫性疾病患者研发创新药,让创新成果惠及更多患者。 积累创新的价值,相信时间的力量。我们从一个个分子开始,向着人类健康蓝图迈进,持续开发创新技术与疗法,并构建完善的全球知识产权和质量管理体系。 我们构建起从源头创新、临床开发、生产到商业化的全产业链平台,致力于为全世界恶性肿瘤和自身免疫性疾病患者开发并提供创新疗法。我们在北京、南京、上海、广州、香港以及美国设有分支机构。 | ||||||||||||||||||||||||
Main Business | 肿瘤及自身免疫性疾病创新药的研发。 | ||||||||||||||||||||||||
Legal Representative | 崔霁松 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | -- | ||||||||||||||||||||||||
Solicitors | 上海市方达律师事务所 | ||||||||||||||||||||||||
Auditors | 天健会计师事务所(特殊普通合伙);安永华明会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 0010-66609913 | ||||||||||||||||||||||||
Fax No | 0010-60702992 | ||||||||||||||||||||||||
Website | www.innocarepharma.com | ||||||||||||||||||||||||
info@innocarepharma.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 21/09/2022 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ -0.370 | ||||||||||||||||||||||||
DPS(RMB)* | -- | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 4.054 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 3.408B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |